| Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. | |
| | |
MedLine Citation:
|
PMID: 20113907 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population. METHODS: We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean +/- standard deviation age, 29.0 +/- 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a change in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics. RESULTS: At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 +/- 0.6; p < 0.001), mean pulmonary artery pressure and pulmonary vascular resistance decreased (p < 0.01), and cardiac output increased (p < 0.001). Twelve patients (13%) experienced at least 1 adverse event. CONCLUSIONS: Bosentan improved exercise capacity, functional class, and cardiopulmonary hemodynamics in this patient cohort and was well tolerated. |
| | |
Authors:
|
Zhi-Cheng Jing; Geoff Strange; Xian-Yang Zhu; Da-Xin Zhou; Jie-Yan Shen; Hong Gu; Zhen-Kun Yang; Xin Pan; Mei-Xiang Xiang; Hua Yao; Dong-Bao Zhao; Brad S Dalton; Zhuo-Li Zhang; Yong Wang; Xian-Sheng Cheng; Yue-Jin Yang |
Related Documents
:
|
1554207 - Recruitment of diffusing capacity with exercise in patients after pneumonectomy. 2924417 - Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced ... 9676057 - Cardiopulmonary exercise testing in the evaluation of patients with occupational asthma... 11082387 - Cardiac exercise hemodynamics late after partial left ventriculectomy. 21660297 - Hypoxemia in patients with copd: cause, effects, and disease progression. 20019617 - Musculoskeletal rehabilitation in the person with scleroderma. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study |
Journal Detail:
|
Title: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Volume: 29 ISSN: 1557-3117 ISO Abbreviation: J. Heart Lung Transplant. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-01 Completed Date: 2010-05-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9102703 Medline TA: J Heart Lung Transplant Country: United States |
Other Details:
|
Languages: eng Pagination: 150-6 Citation Subset: IM |
Affiliation:
|
Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. jingzhicheng@gmail.com <jingzhicheng@gmail.com> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antihypertensive Agents / administration & dosage* China Female Humans Hypertension, Pulmonary / drug therapy* Male Severity of Illness Index Sulfonamides / administration & dosage* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Sulfonamides; 147536-97-8/bosentan |
| Comments/Corrections | |
Comment In:
|
J Heart Lung Transplant. 2010 Feb;29(2):157-8
[PMID:
20113908
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Childhood Immune Thrombocytopenic Purpura: Diagnosis and Management.
Next Document: Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia.